Celyad bounces back from heart study flop to ink a $312M I/O deal with Ono
Just a few days after its stem cell therapy for damaged hearts flunked a mid-stage study, Belgium’s Celyad is back with a Japanese pharma deal for their immuno-oncology work.
Ono Pharmaceutical is hitching its wagon to Celyad’s twist on CAR-T tech. In exchange for $12.5 million in cash and close to $300 million in biobuck milestones, Ono snags the rights to use Celyad’s $CYAD engineered cell tech to develop new cancer therapies for Japan, Korea and Taiwan.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.